Targeting Adaptive Immune System in Alzheimer's Disease by Alireza Faridar, MD 10.6.20
views
Houston Methodist is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine. Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This website uses cookies to improve website functionality and performance, to analyze website traffic, and to provide you with a more personalized experience. To find out more about the cookies we use, see our Digital Privacy Policy, Disclaimer & Terms of Use.Recent findings, including the discovery of risk genes involved in inflammation signaling, indicate that inflammation is critical for the onset and progression of Alzheimer Disease. Regulatory T cells (Tregs) play an important neuroprotective role in suppressing microglia/macrophage-mediated inflammation, as well as modulating adaptive immune reactions. A progressive compromise in the immunomeulatory function of Tregs occurs through the course of Alzheimer disease. Recovering the immunosuppressive capacity of Tregs may serve as a potential immunotherapy to treat Alzheimer pathology.
Recorded in the Houston Methodist Research Institute Ernest H. Cockrell Boardroom R2-311 on Tuesday, October 6, 2020.
Introduction provided by Dr. Stanley Appel, MD, Peggy & Gary Edwards Distinguished Endowed Chair, Stanley H. Appel Department of Neurology, Co-Director, Neurological Institute, Houston Methodist